Supernus Pharmaceuticals (SUPN) Other Accumulated Expenses (2013 - 2026)

Supernus Pharmaceuticals (SUPN) has 14 years of Other Accumulated Expenses data on file, last reported at $83.0 million in Q1 2026.

• On a quarterly basis, Other Accumulated Expenses rose 1647.37% year-over-year to $83.0 million in Q1 2026; TTM through Mar 2026 was $83.0 million, a 1647.37% increase from a year earlier, with the FY2025 full-year figure at $38.2 million, changed N/A from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $83.0 million, up from $38.2 million in the prior quarter.
• Over the last five years, Other Accumulated Expenses for SUPN reached as high as $83.0 million in Q1 2026 and fell as low as $710000.0 in Q3 2023.
• Historically, Other Accumulated Expenses has averaged $17.7 million across 5 years, with a median of $8.4 million in 2022.
• Across the five-year window, Other Accumulated Expenses slumped 91.33% in 2023 and jumped 1647.37% in 2026, its largest moves.
• Year by year, Other Accumulated Expenses stood at $16.9 million in 2022, then sank by 74.6% to $4.3 million in 2023, then fell by 15.41% to $3.6 million in 2024, then surged by 954.98% to $38.2 million in 2025, then soared by 117.06% to $83.0 million in 2026.
• Per Business Quant data, the three most recent Other Accumulated Expenses figures were $83.0 million in Q1 2026, $38.2 million in Q4 2025, and $26.3 million in Q3 2025.